LAG-3-Next Generation Immunotherapy - Competitive Landscape and Market Forecast-2035
LAG-3-Next Generation Immunotherapy Emerging DrugsMGD013: MacroGenicsMGD013 which is being developed by MacroGenics is an IgG4κ bispecific DART molecule that binds to PD-1 and LAG-3 concomitantly or independently and disrupts non-redundant inhibitory pathways to restore shattered T-cell function further. .LAG525: NovartisLAG525 (anti-LAG-3, also known as IMP701) which is under development by Novartis is an investigational immunotherapy being developed to potentially treat a range of solid tumors. The drug is a humanized form of IMP701 is currently being evaluated in five phase I and phase II clinical trials in combination with Novartis' PD-1 inhibitor spartalizumab for the treatment of various cancers. Relatlimab (BMS-986016): Bristol-Myers Squibb Relatlimab (previously known as BMS-986016) is a cancer immunotherapy being developed by Bristol-Myers Squibb (BMS). The treatment has already shown benefit in melanoma patients and is also being tested in other cancers. Immunotherapies use the body's own immune system to fight cancer, instead of directly attacking cancer cells. Eftilagimod Alpha (IMP321): ImmutepEftilagimod alpha (IMP321), a soluble dimeric recombinant form of LAG-3, is a first-in-class antigen presenting cell activator under clinical development. By stimulating dendritic cells through MHC class II molecules, IMP321 was proven to induce sustained immune responses. Combining active immunotherapy with a standard cytotoxic chemotherapy regimen represents a promising novel strategy that might lead to therapeutic improvements in metastatic breast cancer.
According to the publisher's analysis, the market is expected to show positive growth due to the launch of potential upcoming therapies in the LAG-3 target during the forecast period (2022-2035). According to the publisher's analysis, NSCLC will occupy the major market share that is 98.81% by 2035. Also, the total market size for LAG-3 by indications is expected to be USD 3,421 Million by 2035.
(20min delay)